Brookline Capital Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has initiated coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and set a price target of $4.
May 30, 2024 | 9:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Brookline Capital has initiated coverage on Forte Biosciences with a Buy rating and set a price target of $4.
The initiation of coverage with a Buy rating and a specific price target of $4 by Brookline Capital is likely to positively impact the stock price of Forte Biosciences in the short term as it signals confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100